Researchers Submit Patent Application, "Nucleic Acid Carriers And Therapeutic Methods Of Use", for Approval (USPTO 20230136794).

Předmět:
Zdroj: Pharma Business Week; 5/22/2023, p3317-3317, 1p
Abstrakt: The nucleic acid carrier of claim 25, further comprising an oligonucleotide complementary to the central portion of the third oligonucleotide having from 25 to 35 nucleotides, wherein the oligonucleotide complementary to the central portion of the third oligonucleotide forms a double-stranded region with the central portion of the third oligonucleotide. The nucleic acid carrier of claim 25, further comprising an oligonucleotide complementary to the central portion of the first oligonucleotide having from 25 to 35 nucleotides, wherein the oligonucleotide complementary to the central portion of the first oligonucleotide forms a double-stranded region with the central portion of the first oligonucleotide. The nucleic acid carrier of claim 25, further comprising an oligonucleotide complementary to the central portion of the second oligonucleotide having from 25 to 35 nucleotides, wherein the oligonucleotide complementary to the central portion of the second oligonucleotide forms a double-stranded region with the central portion of the second oligonucleotide. [Extracted from the article]
Databáze: Complementary Index